Abstracts tagged "Biologics"

Abstract Number: 2862 • 2018 ACR/ARHP Annual Meeting
Magnitude of Response to TNF Inhibitors in Children with Spondyloarthritis and Sacroiliitis
Rosemary Peterson¹, Rui Xiao², Timothy G. Brandon³, David M. Biko⁴, Michael Francavilla⁴, Nancy A. Chauvin⁵ and Pamela F. Weiss⁶, ¹Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Radiology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁵Radiology, Penn State Hershey Medical Center, Hershey, PA, ⁶Pediatrics, Children's Hospital Philadelphia, Philadelphia, PA
Background/Purpose: We aimed to quantify the magnitude of biologic effect on sacroiliitis in juvenile SpA by comparing the change in the Spondyloarthritis Research Consortium of…
Abstract Number: 286 • 2018 ACR/ARHP Annual Meeting
The Prevalence and Treatment Patterns of Women of Childbearing Age with Rheumatic Diseases
Edward Lee¹, Robert Suruki², Brian Carpenter³, Ty Harkness³, Daniel Luk⁴ and Mohamed Yassine¹, ¹UCB Pharma, Smyrna, GA, ²UCB Pharma, Raleigh, NC, ³Charles River Associates, New York, NY, ⁴Charles River Associates, Boston, MA
Background/Purpose: Emerging data on exposure of infants to therapeutics through placental transfer and breastmilk could impact the management of women of childbearing age (WoCBA) with…
Abstract Number: 702 • 2018 ACR/ARHP Annual Meeting
Effect of Biologics on Radiographic Progression of Peripheral Joints in Patients with Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Dongze Wu¹, Priscilla Wong¹, James F Griffith², Jiang Yue¹ and Lai-Shan Tam³, ¹Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, China, ²Department of Imaging and Interventional Radiology, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, ³Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Psoriatic arthritis (PsA) often leads to structural damage with resultant disability and reduced quality of life. Biologic disease modifying anti-rheumatic drugs (bDMARDs), including tumor…
Abstract Number: 2185 • 2018 ACR/ARHP Annual Meeting
Direct Medical Costs for Medicare Patients with Rheumatoid Arthritis
Andrew Hresko¹, Zhi Zhang², Joshua Colls², Michael E Weinblatt², Nancy A. Shadick² and Daniel Solomon², ¹Tufts University School of Medicine, Boston, MA, ²Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) affects over 1 million Medicare enrollees. Despite the size of this population, costs for RA within Medicare remain poorly understood, especially…
Abstract Number: 2582 • 2018 ACR/ARHP Annual Meeting
Post-Marketing Safety of Secukinumab in Adult Patients with Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Cumulative Analysis across >96,000 Patient-Treatment Years Exposure
Atul A. Deodhar¹, Dafna D Gladman², Iain B. McInnes³, Filip van Den Bosch⁴, Abhijit Shete⁵, Ruquan You⁶, Samina Hussain⁷ and Jorge Safi⁸, ¹Oregon Health & Science University, Portland, OR, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁴Rheumatology, Ghent University Hospital and VIB Ghent University, Gent, Belgium, ⁵Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ⁶Shanghai Novartis Trading Limited, Shanghai, China, ⁷Novartis Healthcare Private Limited, Hyderabad, India, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ
Background/Purpose: Secukinumab, a fully human monoclonal IgG1 antibody that selectively neutralizes IL-17A, is currently approved in >75 countries for use in psoriasis /psoriatic arthritis and…
Abstract Number: 2866 • 2018 ACR/ARHP Annual Meeting
Biologic Refractory Disease in a Cohort Study of Children and Young People with Juvenile Idiopathic Arthritis from the United Kingdom
Eleanor Heaf¹, Lianne Kearsley-Fleet¹, Rebecca Davies¹, Diederik De Cock², Eileen Baildam³, Michael W. Beresford^3,4, Helen E. Foster⁵, Taunton R. Southwood⁶, Wendy Thomson^7,8 and Kimme L. Hyrich^2,8, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ³Clinical Academic Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ⁴Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom, ⁵Newcastle University and Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom, ⁶Institute of Child Health, University of Birmingham and Birmingham Children's Hospital, Birmingham, United Kingdom, ⁷Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁸National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: Biologics are a main treatment option for children and young people with juvenile idiopathic arthritis (JIA) who do not respond or are intolerant to…
Abstract Number: 287 • 2018 ACR/ARHP Annual Meeting
Comparison of Real-World Costs between Patients with Rheumatoid Arthritis Treated with Subcutaneously-Administered Biologics Previously Treated with Another Biologic
Jennie H. Best¹, Paul Juneau² and Amanda Kong², ¹Genentech, Inc., South San Francisco, CA, ²IBM Watson Health, Bethesda, MD
Background/Purpose: To compare real-world healthcare costs between patients with rheumatoid arthritis (RA) who were treated with subcutaneously (SC) administered biologics after previously using at least…
Abstract Number: 881 • 2018 ACR/ARHP Annual Meeting
Association of Comorbidities with DAS28 Disease Status and Remission in Race/Ethnic Groups with Rheumatoid Arthritis
Sharon Dowell¹, Rodolfo Perez-Alamino², Christopher J. Swearingen³, Gail S. Kerr⁴ and Yusuf Yazici⁵, ¹Internal Medicine, Howard University, Washington, DC, ²Rheumatology Department, Hospital de Clínicas Pte. Dr. Nicolás Avellaneda, Tucumán, Argentina, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴Rheumatology, Washington DC VAMC and Georgetown and Howard University, Washington, DC, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Racial/ethnic disparities in comorbidity (CM) in rheumatoid arthritis (RA) may confound treatment and outcomes. Rheumatic Disease Comorbidity Index (RDCI) is a validated tool predicting…
Abstract Number: 2202 • 2018 ACR/ARHP Annual Meeting
The Relationship between Periodontitis and the Treatment Response to Biologics in Rheumatoid Arthritis Patients; A Post-Hoc Analysis Using [18F] Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography
Masahiro Tachibana^1,2, Yukio Yonemoto³, Takahito SUTO³, Koichi OKAMURA³, Chisa OKURA³, Hideo SAKANE³ and Hirotaka CHIKUDA³, ¹Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan, ²Orthopedic Surgery, Kiryu Kosei General Hospital, Kiryu, Japan, ³Orthopaedic Surgery, Gunma University Graduate School of Medicine, MAEBASHI, Japan
Background/Purpose: Rheumatoid arthritis(RA) and periodontitis have been suggested to be related, and they share many clinical and pathologic features. Both diseases are chronic inflammatory diseases…
Abstract Number: 2584 • 2018 ACR/ARHP Annual Meeting
Low Incidence of Both New-Onset and Flares of Uveitis in Secukinumab-Treated Patients with Ankylosing Spondylitis: Clinical Trial and Post-Marketing Safety Analysis
Atul A. Deodhar¹, Corinne Miceli-Richard², Xenofon Baraliakos³, Helena Marzo-Ortega⁴, Dafna D Gladman⁵, Ruvie Martin⁶, Jorge Safi⁷, Brian Porter⁷ and Abhijit Shete⁸, ¹Oregon Health & Science University, Portland, OR, ²Rheumatology Department, Paris Descartes University, Paris, France, ³Ruhr-University Bochum, Herne, Germany, ⁴NIHR LBRC, LTHT and LIRMM, University of Leeds, Leeds, United Kingdom, ⁵Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland
Background/Purpose: Uveitis, a common extra-articular manifestation of spondyloarthritis (SpA), has an estimated prevalence of 33.2% in patients with ankylosing spondylitis (AS), which increases with duration…
Abstract Number: 2875 • 2018 ACR/ARHP Annual Meeting
Identifying Trends in Lines of Therapy Following Initial Biologic Disease-Modifying Antirheumatic Drug in Patients with Rheumatoid Arthritis
Jay Lin¹, Jeannie Choi², Jeffrey R. Curtis³, Melissa Lingohr-Smith¹ and Susan Boklage⁴, ¹Novosys Health, Green Brook, NJ, ²Sanofi, Bridgewater, NJ, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Among patients with rheumatoid arthritis (RA) who have an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), the addition of a biologic DMARD…
Abstract Number: 291 • 2018 ACR/ARHP Annual Meeting
Factors Associated with High-Dose Corticosteroid Use in SLE Patients Post Initiation of SLE Therapy
Krista Schroeder¹, Steve Gelwicks¹, Jim Paik² and Robert W. Hoffman¹, ¹Eli Lilly and Company, Indianapolis, IN, ²HEOR, Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Systemic lupus erythematosus (SLE) therapies include non-steroidal anti-inflammatory drugs, antimalarials, systemic immunosuppressants, and biologics with corticosteroids as necessary. The majority of these current therapies…
Abstract Number: 910 • 2018 ACR/ARHP Annual Meeting
In Diagnostic Prevalence and Treatment Patterns of Male and Female Ankylosing Spondylitis Patients in the United States, 2006-2016
Jessica Walsh¹, Theresa Hunter², Rebecca Bolce², David Sandoval Calderon² and Krista Schroeder², ¹University of Utah School of Medicine, Salt Lake City, UT, USA, Salt Lake City, UT, ²Eli Lilly and Company, Indianapolis, IN
Background/Purpose: This study aimed to analyze the prevalence rates and treatment patterns of male and female ankylosing spondylitis (AS) patients in the United States (US)…
Abstract Number: 2203 • 2018 ACR/ARHP Annual Meeting
Atherosclerotic Inflammation in Rheumatoid Arthritis Patients: A Post-Hoc Study Using Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography
Yukio Yonemoto¹, Masahiro Tachibana², Koichi OKAMURA¹, Takahito SUTO¹, Hideo SAKANE¹, Chisa OKURA¹, Tetsuya Kaneko² and Hirotaka CHIKUDA¹, ¹Orthopaedic Surgery, Gunma University Graduate School of Medicine, MAEBASHI, Japan, ²Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan
Background/Purpose: Rheumatoid arthritis (RA) has long been associated with an increased cardiovascular risk, and despite substantial improvements in disease management, its associated mortality remains high.…
Abstract Number: 2585 • 2018 ACR/ARHP Annual Meeting
Secukinumab Immunogenicity in Patients with Psoriatic Arthritis and Ankylosing Spondylitis during a 52-Week Treatment Period
Atul A. Deodhar¹, Dafna D Gladman², Iain B. McInnes³, Vibeke Strand⁴, Mengyuan Ren⁵, Sebastian Spindeldreher⁶, Luminita Pricop⁷, Brian Porter⁷, Jorge Safi⁷, Abhijit Shete⁸ and Gerard Bruin⁶, ¹Oregon Health & Science University, Portland, OR, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁴Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁵Novartis Pharmaceuticals, Shanghai, China, ⁶Novartis Institutes for BioMedical Research, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland
Background/Purpose: Secukinumab, a fully human monoclonal IgG1 antibody (mAb) that selectively targets IL-17A, is efficacious for the treatment of psoriasis, psoriatic arthritis (PsA) and ankylosing…

« Previous Page
1
…
4
5
6
7
8
…
29
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].